Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01590888 · ClinicalTrials.gov registry record · Phase 2
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
A Phase 2 study of Huntington Disease, sponsored by Prana Biotechnology Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 109
- Enrollment target
- 19
- Study locations
NCT01590888: Completed Phase 2 study of Huntington Disease, sponsored by Prana Biotechnology Limited.
NCT01590888 is a Phase 2 study of Huntington Disease that has completed, run by Prana Biotechnology Limited. The registered enrollment target is 109 participants, below the 632-participant average among 35 other Huntington Disease trials with a reported enrollment target (83% lower). The trial reports 19 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01590888, a Phase 2 study of Huntington Disease, has completed, sponsored by Prana Biotechnology Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 109 participants
- Enrollment target
- 19
- Study locations
Study Summary
Huntington disease (HD) is an inherited neurodegenerative disease which affects over 30,000 people in both the United States and Australia. HD is characterized by brain cell death that usually begins between the ages of 30 to 50, and results in motor, cognitive and behavioral signs and symptoms. While there are medications to help relieve some of the disease symptoms, there is no known treatment to address the cognitive impairment associated with HD. Normally occurring metals in the brain play a significant role in diseases such as Alzheimer disease and HD. PBT2 is a drug designed to interrupt interactions between these biological metals and target proteins in the brain, to prevent deterioration of brain cells. PBT2, has shown in animal models, and as well as in a small group of patients with Alzheimer's disease, it may improve cognition. There is some indication in animal models of HD, that the drug may improve motor function and control and reduce the amount of brain cell degeneration. PBT2-203 will evaluate how safe and well tolerated PBT2 is at a dose of 100 mg or 250 mg a day administered as oral daily capsules compared to a placebo over a six month treatment period. The trial will also measure whether there is an effect on cognitive abilities as well as other HD symptoms including motor and overall functioning of individuals with HD.
Primary Outcome
As measured by the total number of participants in each dose group who reported at least one adverse events during the study,
Conditions Studied
Interventions
- DRUG Placebo
- DRUG PBT2
Study Locations (19)
Victoria
- Calvary Health Care Bethlehem - Clayton
- University of Melbourne Normanby Unit - St Vincents/St Georges - Melbourne
- Royal Melbourne Hospital - Parkville
Maryland
- University of Maryland School of Medicine - Baltimore
- Johns Hopkins University - Baltimore
New York
- Albany Medical College - Albany
- Columbia University Medical Center - New York
California
- University of California San Diego - San Diego
Colorado
- Colorado Neurological Institute - Englewood
Connecticut
- University of Connecticut Health Center - Farmington
Florida
- University of Miami - Miami
Massachusetts
- Massachusetts General Hospital East - Charlestown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2012-04 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
What the finished NCT01590888 record still lists
NCT01590888 is an interventional study that assigns participants to a tested intervention. The registered 109 participants enrollment target is mid-sized for trials with a published cap, below the 632-participant average among 35 other Huntington Disease trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Huntington Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01590888 lists 19 locations in 15 states (Victoria, Maryland, New York).
Frequently Asked Questions
What is clinical trial NCT01590888 about?
NCT01590888 is a clinical study titled "Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease". Huntington disease (HD) is an inherited neurodegenerative disease which affects over 30,000 people in both the United States and Australia. HD is characterized by brain cell death that usually begins between the ages of 30 to 50, and results in motor, cognitive and behavioral signs and symptoms. Whi...
What is the current status of trial NCT01590888?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 109 participants. The study started on 2012-04. Estimated completion is 2014-02.
What conditions does trial NCT01590888 study?
This clinical trial studies the following conditions: Huntington Disease.
What interventions are being tested in trial NCT01590888?
The interventions under investigation include: Placebo (DRUG), PBT2 (DRUG).
Who is sponsoring clinical trial NCT01590888?
This trial is sponsored by Prana Biotechnology Limited, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01590888 being conducted?
This trial has 19 study locations across California, Colorado, Connecticut, Florida, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Huntington Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01590888's enrollment target sits among peer trials
109 18th of 35 higher than 18 of 35 other Huntington Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Huntington Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease
ACTIVE NOT RECRUITING · Phase 2
-
Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease
ACTIVE NOT RECRUITING · Phase 2
-
Creatine Safety and Tolerability in Premanifest HD: PRECREST
COMPLETED · Phase 2
-
Atomoxetine and Huntington's Disease
COMPLETED · Phase 2
-
A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease
COMPLETED · Phase 2
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02421380 · 109 participants · NA
Characterization of Hyperpolarized Pyruvate MRI Reproducibility
- NCT04526600 · 109 participants · NA
Fidgeting and Attentional and Emotional Regulation in ADHD
- NCT04835584 · 109 participants · Phase 1
KRT-232 and TKI Study in Chronic Myeloid Leukemia
- NCT06626516 · 109 participants · Phase 1
Tebentafusp-tebn With LDT in Metastatic UM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia